Reports Q2 revenue $47.4M, consensus $47.37M. “Our base revenue, which excludes revenue from high-volume CleanCap, grew 5% in the quarter, led by strong demand for our Cygnus products and services,” said Bernd Brust, CEO, Maravai LifeSciences (MRVI).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences Announces Major Organizational Restructuring
- Maravai Lifesciences Holdings, Inc. (MRVI) Q2 Earnings Cheat Sheet
- Strategic Leadership Changes and Financial Discipline Drive Buy Rating for Maravai Lifesciences Holdings
- Maravai Lifesciences Appoints New CFO Rajesh Asarpota
- Maravai Lifesciences CFO Kevin Herde to switch roles, Rajesh Asarpota to succeed